Sexual Hormones in Human Skin

Total Page:16

File Type:pdf, Size:1020Kb

Load more

Review 85 Sexual Hormones in Human Skin Authors C. C. Zouboulis 1 , 2 , W . - C . C h e n 3 , M . J . T h o r n t o n4 , K. Qin 5 , R . R o s e n fi eld 5 , 6 Affi liations Affi liation addresses are listed at the end of the article Key words Abstract the development of hyperandrogenism and the ᭹ ᭤ androgens & associated skin diseases such as acne, sebor- ᭹᭤ estrogens The skin locally synthesizes signifi cant amounts rhoea, hirsutism and androgenetic alopecia. On ᭹᭤ progestins of sexual hormones with intracrine or paracrine the other hand, estrogens have been implicated ᭹ ᭤ human skin actions. The local level of each sexual steroid in skin aging, pigmentation, hair growth, sebum ᭹ ᭤ acne depends upon the expression of each of the production and skin cancer. Estrogens exert androgen- and estrogen-synthesizing enzymes their actions through intracellular receptors or in each cell type, with sebaceous glands and via cell surface receptors, which activate specifi c sweat glands being the major contributors. second messenger signaling pathways. Recent Sebocytes express very little of the key enzyme, studies suggest specifi c site-related distribution cytochrome P450c17, necessary for synthesis of ER and ER in human skin. In contrast, pro- of the androgenic prohormones dehydroepi- gestins play no role in the pathogenesis of skin androsterone and androstenedione, however, disorders. However, they play a major role in the these prohormones can be converted by sebo- treatment of hirsutism and acne vulgaris, where cytes and sweat glands, and probably also by they are prescribed as components of estrogen- dermal papilla cells, into more potent androgens progestin combination pills and as anti-andro- like testosterone and dihydrotestosterone. Five gens. These combinations enhance gonadotropin major enzymes are involved in the activation suppression of ovarian androgen production. and deactivation of androgens in skin. Andro- Estrogen-progestin treatment can reduce the gens affect several functions of human skin, need for shaving by half and arrest progression such as sebaceous gland growth and differentia- of hirsutism of various etiologies, but do not nec- tion, hair growth, epidermal barrier homeostasis essarily reverse it. However, they reliably reduce and wound healing. Their effects are mediated acne. Cyproterone acetate and spironolactone are by binding to the nuclear androgen receptor. similarly effective as anti-androgens in reducing received 23. 11. 2006 Changes of isoenzyme and / or androgen recep- hirsutism, although there is wide variability in accepted 28. 11. 2006 tor levels may have important implications in individual responses. Bibiliography DOI 10.1055/s-2007-961807 Introduction unit to androgens that is not yet completely Horm Metab Res 2007; & understood [3] . 39: 85 – 95 Several functions of the human skin appear © Georg Thieme Verlag KG Stuttgart · New York · strongly dependent on biologically active sexual ISSN 0018-5043 hormones, namely androgens, estrogens, and Androgens and skin progestins. Their effect is mediated by binding to & Correspondence nuclear receptors, and lack of functional recep- Androgens relevant to the skin C. C. Zouboulis tors prevents the action of sexual hormones on Among the circulating androgens, dehydroepian- Departments of Dermato- the skin [1] . The effects of sexual hormones can drosterone (DHEA) and DHEA sulfate (DHEA-S) logy and Immunology · Dessau differ from cell type to cell type and among cells are predominantly produced in the adrenal cor- Medical Center · Auenweg of different locations [2] . Androgen effects on the 38 · 06847 Dessau · Germany tex. Androstenedione is produced approximately Tel.: + 49 / 340 / 501 40 00 pilosebaceous unit are best known and best char- equally by the adrenal cortex and the ovaries, Fax: + 49 / 340 / 501 40 25 acterized. Nevertheless there is considerable and somewhat less by the testes [4] . These are christos.zouboulis@klinikum- variability in the response of the pilosebaceous weak prohormones that act only after conversion dessau.de Zouboulis CC et al. Sexual Hormones in Skin … Horm Metab Res 2007; 39: 85– 95 86 Review to the more potent androgens, testosterone and 5 -dihydrotes- with sebaceous glands and sweat glands being the major con- tosterone (DHT). Testosterone is mainly secreted by the testes in tributors [9, 17] . males beginning at puberty; in reproductive-age females it The skin, especially sebocytes, is capable of synthesizing choles- arises almost equally from the ovary and adrenal cortex by a terol, which is utilized in cell membranes, formation of the epi- combination of secretion and conversion of androstenedione in dermal barrier and sebum; however, sebocytes express very peripheral organs. DHT is mainly synthesized in peripheral little of the key enzyme, cytochrome P450c17, necessary for syn- organs, including skin, in both genders. thesis of the androgenic prohormones DHEA and androstenedi- Testosterone, particularly free testosterone, is the major circu- one [18] . However, DHEA and androstenedione, and possibly lating androgen because of its concentration and potency [3] . DHEA-S, can be converted by sebocytes and sweat glands, and The less potent DHEA-S is the androgen with by far the highest probably also by dermal papilla cells, into more potent andro- serum concentration in both sexes and is related to sebum pro- gens like testosterone and DHT [2] . Five major enzymes are duction prepubertally [5] and to cystic acne in adults [6] . Andros- involved in the activation and deactivation of androgens in skin tenedione and DHEA have also been shown to stimulate sebum [19] . In a fi rst step, steroid sulfatase hydrolyzes DHEA-S to DHEA secretion in humans [7] . Male levels of testosterone stimulate in skin [20] . The sebaceous gland has been suggested to carry full axillary and pubic hair growth, but in the absence of DHT out this reaction since strong steroid sulfatase immunoreactivity formation do not suffi ce to stimulate male beard growth and was found in acne skin, primarily associated with the monocytes scalp hair recession [8] . infi ltrating the lesions [21] , but further evidence is required to corroborate this preliminary report. This enzyme activity has The androgen receptor and skin also been detected in the dermal papillae of human terminal Testosterone and DHT act through a single nuclear receptor, the hair follicles [22] . Subsequently, 3 -hydroxysteroid dehydroge- androgen receptor (AR), with DHT being the more active ligand nase / 5 – 4 -isomerase (3 -HSD) converts DHEA to androstenedi- [9] . AR is an X-chromosome-encoded, ligand-activated, intracel- one. Two isoforms of this enzyme have been described. Human lular transcription factor that belongs to the steroid/ nuclear skin seems to express exclusively the type 1 isoform. Several receptor superfamily [2, 10] . Like all nuclear receptors, AR is a studies led to the conclusion that type 1 3 -HSD is mainly soluble molecule with a proclivity for employing transcriptional located in the sebaceous glands [17] . regulation as a means of promoting its biological effects. In com- In a further step, androstenedione is activated by conversion to mon with other steroid receptors, AR is compartmentalized in testosterone through androgenic 17 -hydroxysteroid dehydro- the cytoplasm, where it exists in polymeric complexes that genase (17 -HSD). The cutaneous expression of 17 -HSD was include the heat shock proteins hsp 90, hsp 70, and hsp 56. Asso- mainly demonstrated in the pilosebaceous unit and epidermal ciation of androgens with AR results in dissociation of the heat keratinocytes. To date, twelve isoforms of this enzyme have been shock proteins. This in turn exposes a nuclear translocation sig- identifi ed [19, 23] . 17 -HSD types 3 and 5 form the active andro- nal previously buried in the receptor structure and initiates gen testosterone from androstenedione, whereas the oxidative transport of the ligand-receptor complex to the nucleus. There, reaction of 17 -HSD types 2 and 4 is in the reverse direction, AR occupies androgen response elements in the promoter regions inactivating the potent sexual steroids. The human sebaceous of androgen-regulated genes to initiate the signaling cascade. gland possesses the cellular machinery needed to transcribe the AR is present in epidermal and follicular keratinocytes, sebo- genes for 17 -HSD types 1– 5; among them a strong 17 -HSD2 cytes, sweat gland cells, dermal papilla cells, dermal fi broblasts, and 17 -HSD5 expression have been reported [17, 18, 24] . The endothelial cells, and genital melanocytes [11, 12] . It is stabilized predominance of the strongly pro-oxidative 17 -HSD2 suggests by ligand binding and is up-regulated in genital skin fi broblasts its protective role against the effects of locally excessive amounts and sebocytes [13, 14] . of potent androgens [18] . Greater reductive activity of andro- Polymorphisms that confer enhanced receptor activity have genic17 -HSD types 3 and 5 was noted in sebaceous glands from been variably associated with the androgen-dependent skin dis- the facial than from non-acne prone areas, suggesting an orders. Studies of CAG trinucleotide repeats have shown them to increased net production of potent androgens in facial areas. In have been inconsistently related to hirsutism [9, 15] . Failure to addition, 17 -HSD3 expression was detected in human sebo- account for possible skewed X-inactivation of the affected alle- cytes, but not in keratinocytes, further indicating the importance
Recommended publications
  • 1 Structure and Function of the Skin

    1 Structure and Function of the Skin

    Go Back to the Top To Order, Visit the Purchasing Page for Details 1 Chapter 1 Structure and Function of the Skin The skin is the human body’s its largest organ, covering 1.6 m2 of surface area and accounting for approximate- ly 16% of an adult’s body weight. In direct contact with the outside environment, the skin helps to maintain four essential bodily functions: ① retention of moisture and prevention of permeation or loss of other molecules, ② regulation of body temperature, ③ protection of the body from microbes and harmful external influences, and ④ sensation. To understand cutaneous biology and skin diseases, it is very important to learn the structure and functions of normal human skin. A. Skin surface The skin surface is not smooth, but is laced with multiple net- works of fine grooves called sulci cutis. These can be deep or shallow. The slightly elevated areas that are surrounded by shal- lower areas of sulci cutis are called cristae cutis. Sweat pores fed crista cutis by the sweat glands open to the cristae cutis (Fig. 1.1). The orientation of the sulci cutis, which differs depending on body location, is called the dermal ridge pattern. Fingerprints and sulcus cutis patterns on the palms and soles, which are unique to each person, are formed by the sulci cutis. Elastic fibers also run in specific directions in deeper parts of the skin, with the direction depend- aabcdefg h i j klmnopqr ing on the site. Some skin diseases, such as epidermal nevus, are known to occur along specific lines distributed over the body, the Blaschko lines (Fig.
  • Safety Data Sheet

    Safety Data Sheet

    SAFETY DATA SHEET SECTION 1: PRODUCT IDENTIFICATION PRODUCT NAME DHEA (Prasterone) (Micronized) PRODUCT CODE 0733 SUPPLIER MEDISCA Inc. Tel.: 1.800.932.1039 | Fax.: 1.855.850.5855 661 Route 3, Unit C, Plattsburgh, NY, 12901 3955 W. Mesa Vista Ave., Unit A-10, Las Vegas, NV, 89118 6641 N. Belt Line Road, Suite 130, Irving, TX, 75063 MEDISCA Pharmaceutique Inc. Tel.: 1.800.665.6334 | Fax.: 514.338.1693 4509 Rue Dobrin, St. Laurent, QC, H4R 2L8 21300 Gordon Way, Unit 153/158, Richmond, BC V6W 1M2 MEDISCA Australia PTY LTD Tel.: 1.300.786.392 | Fax.: 61.2.9700.9047 Unit 7, Heritage Business Park 5-9 Ricketty Street, Mascot, NSW 2020 EMERGENCY PHONE CHEMTREC Day or Night Within USA and Canada: 1-800-424-9300 NSW Poisons Information Centre: 131 126 USES Adjuvant; Androgen SECTION 2: HAZARDS IDENTIFICATION GHS CLASSIFICATION Toxic to Reproduction (Category 2) PICTOGRAM SIGNAL WORD Warning HAZARD STATEMENT(S) Reproductive effector, prohormone. Suspected of damaging fertility or the unborn child. May cause harm to breast-fed children. Causes serious eye irritation. Causes skin and respiratory irritation. Very toxic to aquatic life with long lasting effects. AUSTRALIA-ONLY HAZARDS Not Applicable. PRECAUTIONARY STATEMENT(S) Prevention Wash thoroughly after handling. Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Do not breathe dusts or mists. Do not eat, drink or smoke when using this product. Avoid contact during pregnancy/while nursing. Wear protective gloves, protective clothing, eye protection, face protection. Avoid release to the environment. Response IF ON SKIN (HAIR): Wash with plenty of water.
  • Dermoscopy of Aplasia Cutis Congenita: a Case Report and Review of the Literature

    Dermoscopy of Aplasia Cutis Congenita: a Case Report and Review of the Literature

    Dermatology Practical & Conceptual Dermoscopy of Aplasia Cutis Congenita: A Case Report and Review of the Literature Rasna Neelam1, Mio Nakamura2, Trilokraj Tejasvi2 1 University of Michigan Medical School, Ann Arbor, MI, USA 2 Department of Dermatology, University of Michigan, Ann Arbor, MI, USA Key words: aplasia cutis congenita, alopecia, dermoscopy, trichoscopy Citation: Neelam R, Nakamura M, Tejasvi T. Dermoscopy of aplasia cutis congenita: a case report and review of the literature. Dermatol Pract Concept. 2021;11(1):e2021154. DOI: https://doi.org/10.5826/dpc.1101a154 Accepted: September 28, 2020; Published: January 29, 2021 Copyright: ©2021 Neelam et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License BY-NC-4.0, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original author and source are credited. Funding: None. Competing interests: The authors have no conflicts of interest to disclose. Authorship: All authors have contributed significantly to this publication. Corresponding author: Trilokraj Tejasvi, MD, Department of Dermatology, University of Michigan, 1910 Taubman Center, 1500 E. Medical Center Dr, Ann Arbor, MI 48109, USA Email: [email protected] Introduction throbbing, and point tenderness in one of the patches of alo- pecia. The alopecic patch had been present on the right pari- Aplasia cutis congenita (ACC) is a rare heterogeneous con- etal-occipital scalp since birth and has been stable in size and genital disorder characterized by focal or widespread absence appearance for years. Three other round patches of alopecia of the skin. had also been present since birth and remained asymptomatic.
  • Vaginal Delivery System

    Vaginal Delivery System

    (19) & (11) EP 2 062 568 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 27.05.2009 Bulletin 2009/22 A61K 9/00 (2006.01) (21) Application number: 07397042.8 (22) Date of filing: 22.11.2007 (84) Designated Contracting States: • Hanes, Vladimir AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Tarrytown, NY 10591 (US) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE • Keinänen, Antti SI SK TR 20540 Turku (FI) Designated Extension States: • Holmberg, Svante AL BA HR MK RS 20900 Turku (FI) • Nikander, Hannu (71) Applicant: Bayer Schering Pharma Oy 21330 Paattinen (FI) 20210 Turku (FI) (74) Representative: Matilainen, Mirja Helena et al (72) Inventors: Oy Jalo Ant-Wuorinen AB, • Talling, Christine Iso Roobertinkatu 4-6 A 20610 Turku (FI) 00120 Helsinki (FI) (54) Vaginal delivery system (57) The present invention is related to an intravag- brane (3) encasing the core, said core and membrane inal delivery system for the controlled release of a pro- essentially consisting of a same or different polymer com- gestogen and an estrogen, comprising additionally a position, wherein at cast one of the cores comprises a therapeutically active or a health-promoting substance progestogen or a mixture of a progestogen and an es- (1) capable of giving and/or enhancing the protection trogen, and another core may comprise an estrogen or against bacterial and fungal infections, and/or enhancing a progestogen, and wherein the membrane or the surface the protection against sexually transmitted diseases. The of the membrane or at least one of the cores comprises delivery system consists of one or more compartments said therapeutically active or a health-promoting sub- (2,4,5), one of each comprising a core (7) and a mem- stance.
  • Vargas KEA, Et Al. Hepatotoxicity Associated with Methylstenbolone and Copyright© Vargas KEA, Et Al

    Vargas KEA, Et Al. Hepatotoxicity Associated with Methylstenbolone and Copyright© Vargas KEA, Et Al

    1. Medical Journal of Clinical Trials & Case Studies ISSN: 2578-4838 Hepatotoxicity Associated with Methylstenbolone and Stanozolol Abuse Vargas KEA*, Guaraná TA, Biccas BN, Agoglia LV, Carvalho ACG, Case Report Gismondi R and Esberard EBC Volume 2 Issue 5 Received Date: July 27, 2018 Department of Gastroenterology/Hepatology, Department of Clinical Medicine, and Published Date: September 03, 2018 Department of Pathology, Antônio Pedro University Hospital, Federal Fluminense DOI: 10.23880/mjccs-16000176 University, Rio de Janeiro, Brazil *Corresponding author: Vargas Karen Elizabeth Arce, Department of Gastroenterology/Hepatology, Department of Clinical Medicine, and Department of Pathology, Antônio Pedro University Hospital, Federal Fluminense University, Rio de Janeiro, Ernani do Amaral Peixoto Avenue, 935. Ap.901 / Cep.24020043, Brazil, Tel: 005521981584624; Email: [email protected] Abstract Background & Objectives: Drug hepatotoxicity is a major cause of liver disease. Many drugs are well known to induce liver damage. Some toxic products, like anabolic androgenic steroids, that are pharmaceutical preparations since they contain pharmaceutically active substance, are available as nutritional supplements. Many patients are used to consume these like dietary stuff. Methods: We introduce a case series of two patients who developed hepatic damage after the consumption of anabolic- androgenic steroids, accompanied by a detailed bibliographic research on this topic. Results: We present two young men who developed significant liver damage, both with hyperbilirubinemia pattern after consumption of anabolic-androgenic steroids. This was associated with considerable morbidity, although both recovered without liver transplantation. The two anabolic-androgenic steroids were being marketed as dietary supplements. Conclusions: Although not well controlled substances in Brazil, anabolic-androgenic steroids are cause of severe hepatotoxicity.
  • Substrate Inhibition of 17 Beta-Hydroxysteroid Dehydrogenase Type 1 in Living Cells and Regulation Among the Steroid-Converting Enzymes in Breast Cancers

    Substrate Inhibition of 17 Beta-Hydroxysteroid Dehydrogenase Type 1 in Living Cells and Regulation Among the Steroid-Converting Enzymes in Breast Cancers

    Substrate inhibition of 17 beta-hydroxysteroid dehydrogenase type 1 in living cells and regulation among the steroid-converting enzymes in breast cancers Thèse Hui Han Doctorat en médecine moléculaire Philosophiæ doctor (Ph. D.) Québec, Canada © Hui Han, 2018 Substrate inhibition of 17 beta-hydroxysteroid dehydrogenase type 1 in living cells and regulation among the steroid-converting enzymes in breast cancers Thèse Hui Han Sous la direction de : Sheng-xiang Lin, directeur de recherche RÉSUMÉ Cette étude a permis de démontrer les fonctions et les mécanismes de la 17bêta- hydroxystéroïde déshydrogénase de type 1 (17β-HSD1) et de la stéroïde sulfatase (STS) au niveau du cancer du sein, y compris la cinétique moléculaire et cellulaire, la liaison du ligand étudiée par la titration de fluorescence, la régulation des stéroïdes et la régulation mutuelle entre les enzymes stéroïdiennes et les cellules cancéreuses du sein. 1), L’inhibition de la 17β-HSD1 par son substrat a été démontrée par la cinétique enzymatique au niveau cellulaire pour la première fois, soutenant ainsi la fonction biologique de l’inhibition produite par le substrat. 2), En tant qu’inhibiteur, la dihydrotestostérone (DHT) n’a pas affecté la concentration du substrat estrone (E1) à laquelle l’activité enzymatique a commencé à diminuer, mais certaines augmentations de vitesse ont été observées, suggérant une diminution significative de l’inhibition par le substrat. 3), Les résultats de la modulation de l’ARNm ont démontré que la transcription du gène codant la 17β-HSD7 diminuait en réponse à l’inhibition de la 17β-HSD1 ou au knockdown dans les cellules du cancer du sein par la modification estradiol (E2).
  • A Case of Acquired Smooth Muscle Hamartoma on the Sole

    A Case of Acquired Smooth Muscle Hamartoma on the Sole

    Ann Dermatol (Seoul) Vol. 21, No. 1, 2009 CASE REPORT A Case of Acquired Smooth Muscle Hamartoma on the Sole Deborah Lee, M.D., Sang-Hyun Kim, M.D., Soon-Kwon Hong, M.D., Ho-Suk Sung, M.D., Seon-Wook Hwang, M.D. Department of Dermatology, Busan Paik Hospital, College of Medicine, Inje University, Busan, Korea A smooth muscle hamartoma is a benign proliferation of INTRODUCTION smooth muscle bundles within the dermis. It arises from smooth muscle cells that are located in arrector pili muscles, Smooth muscle hamartomas (SMH) are a result of benign dartos muscles, vascular smooth muscles, muscularis proliferation of smooth muscle bundles in the dermis. SMH- mammillae and the areolae. Acquired smooth muscle associated smooth muscle cells originate from arrector hamartoma (ASMH) is rare, with only 10 such cases having pili-, dartos-, vulvar-, mammillary- and vascular wall- been reported in the English medical literature to date. Most muscles1-3. SMH is characterized by slightly pigmented of these cases of ASMH were shown to have originated from plaques that contain vellus hairs, and SMH is subdivided arrector pili and dartos muscles. Only one case was reported into two types: congenital smooth muscle hamartoma to have originated from vascular smooth muscle cells. A 21 (CSMH) and acquired smooth muscle hamartoma (ASMH)1-3. year-old woman presented with a tender pigmented nodule, ASMH is a very rare form of SMH that was first described with numbness, on the sole of her foot, and this lesion had by Wong and Solomon1 in 1985, with only such 10 cases developed over the previous 18 months.
  • Records of Pharmaceutical and Biomedical Sciences

    Records of Pharmaceutical and Biomedical Sciences

    REVIEW ARTICLE RECORDS OF PHARMACEUTICAL AND BIOMEDICAL SCIENCES Effect of Exogenous Anabolic Androgenic Steroids on Testosterone/ Epitestosterone Ratio and its Application on Athlete Biological Passport in Egypt Hanem A. Khalil a, Dina M. Abo-Elmatty b, Rosa V. Alemany c, Noha M. Mesbah b a Egyptian Anti-Doping Organization, Cairo, Egypt. b Faculty of Pharmacy, Department of Biochemistry Suez Canal University, Ismailia, Egypt. C Catalonian Anti-Doping Laboratory of Fundacio IMIM, Barcelona, Spain. Abstract Received on: 01.09. 2018 Using the Anabolic Androgenic Steroid (AAS) agents is evident not only Revised on: 21. 10. 2018 within the competitive senior and junior athletes, but also in non-sporting contexts by individuals seeking to „improve‟ their physique. No accurate data Accepted on: 01. 11. 2018 is available for the prevalence of AAS misuse among athletes. Studies suggest that it may be 1–5% of the population; with the prevalence being higher in males. Many studies documented side effects and health hazards with the misuse of anabolic steroids, where these were accused as a cause of Correspondence Author: deaths among athletes. Intake of exogenous anabolic steroids disturbed the Testosterone / Epitestosterone (T/E) ratio causing its evaluation above the Tel:+201270206648. normal level. This review outlines the anabolic steroids, its side effects and E-mail address: health impacts in both the sporting and physique development contexts. It also provides a brief review of the history of AAS as doping agents and [email protected] athlete biological passport. Conclusion: Doping among athletes is a widespread public health and social problem. Many studies have shown that both short- and long-term health complications have consequences and dependencies.
  • Estriol Therapy for Autoimmune and Neurodegenerative Diseases and Disorders

    Estriol Therapy for Autoimmune and Neurodegenerative Diseases and Disorders

    (19) TZZ¥Z__T (11) EP 3 045 177 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 20.07.2016 Bulletin 2016/29 A61K 31/565 (2006.01) A61K 31/566 (2006.01) A61K 31/568 (2006.01) A61K 45/06 (2006.01) (2006.01) (2006.01) (21) Application number: 16000349.7 A61K 31/785 A61P 25/00 (22) Date of filing: 26.09.2006 (84) Designated Contracting States: (72) Inventor: Voskuhl, Rhonda R. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Los Angeles, CA 90024 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR (74) Representative: Müller-Boré & Partner Patentanwälte PartG mbB (30) Priority: 26.09.2005 US 720972 P Friedenheimer Brücke 21 26.07.2006 US 833527 P 80639 München (DE) (62) Document number(s) of the earlier application(s) in Remarks: accordance with Art. 76 EPC: This application was filed on 11-02-2016 as a 13005320.0 / 2 698 167 divisional application to the application mentioned 06815626.4 / 1 929 291 under INID code 62. (71) Applicant: The Regents of the University of California Oakland, CA 94607 (US) (54) ESTRIOL THERAPY FOR AUTOIMMUNE AND NEURODEGENERATIVE DISEASES AND DISORDERS (57) The present invention relates to a dosage from comprising estriol and glatiramer acetate polymer-1 for use in the treatment of multiple sclerosis (MS), as well as to a kit comprising estriol and glatiramer acetate polymer-1. EP 3 045 177 A1 Printed by Jouve, 75001 PARIS (FR) EP 3 045 177 A1 Description [0001] This invention was made with Government support under Grant No.
  • Gen Anat-Skin

    Gen Anat-Skin

    SKIN • Cutis,integument • External covering • Skin+its appendages-- -integumentary system • Largest organ---15 to 20% body mass. LAYERS • Epidermis •Dermis Types • Thick and thin(1-5 mm thick) • Hairy and non hairy Thick skin EXAMPLES • THICK---PALMS AND SOLES BUT ANATOMICALLY THE BACK HAS THICK SKIN. REST OF BODY HAS THIN SKIN • NON HAIRY----PALMS AND SOLES,DORSAL SURFACE OF DISTAL PHALANX,GLANS PENIS,LABIA MINORA,LABIA MAJORA AND UMBLICUS FUNCTIONS • Barrier • Immunologic • Homeostasis •Sensory • Endocrine • excretory EPIDERMIS(layers) • Stratum basale or stratum germinativum • Stratum spinosum • Stratum granulosum • Stratum lucidum • Stratum corneum Type of cells in epidermis and keratinization • Keratinocytes • Melanocytes • Langerhans • Merkels cells DERMIS LAYERS---- 1.PAPILLARY • Dermal papillae • Complementary epidermal ridges or rete ridges • Dermal ridges in thick skin • Hemidesmosomes present both in dermis and epidermis RETICULAR LAYER •DENSE IRREGULAR CONNECTIVE TIISUE Sensory receptors • Free nerve endings • Ruffini end organs • Pacinian and • Meissners corpuscles Blood supply • Fasciocutaneous A • Musculocutaneous A • Direct cutaneous A APPENDAGES • Hair follicle producing hair • Sweat glands(sudoriferous) • Sebaceous glands • Nails Hair follicle • Invagination of epidermis • Parts---infundibulum, isthmus, inferior part having bulb and invagination HAIR follicle layers • Outer and inner root sheath • Types of hair vellus, terminal, club • Phases of growth— anagen, catagen and telogen Hair shaft • Cuticle •Cortex • Medulla
  • Reproductive DHEA

    Reproductive DHEA

    Reproductive DHEA Analyte Information - 1 - DHEA Introduction DHEA (dehydroepiandrosterone), together with other important steroid hormones such as testosterone, DHT (dihydrotestosterone) and androstenedione, belongs to the group of androgens. Androgens are a group of C19 steroids that stimulate or control the development and maintenance of male characteristics. This includes the activity of the male sex organs and the development of secondary sex characteristics. Androgens are also precursors of all estrogens, the female sex hormones. DHEA (dehydroepiandrosterone) is the aromatic C19-steroid composed of a 10,13-dimethyl, 3-hydroxy group and 17-ketone. Its chemical name is 3β-hydroxy-5-androsten-17-one, its summary formula is C19H28O2, and its molecular weight (Mr) is 288.4 Da. The structural formulas of DHEA and related androgens are shown in Fig.1 Fig.1: Structural formulas of the most important androgens DHEA Androstenedione Testosterone Dihydrotestosterone There are more than 40 other names used for DHEA, including: (+)-Dehydroisoandrosterone; (3beta, 16alpha)-3,16-dihydroxy-androst-5-en- 17-one; 5,6-Dehydroisoandrosterone; 17-Chetovis, 17-Hormoforin, Andrestenol, Diandron, Prasterone and so on. As DHEA is very closely connected with its sulfate form DHEA-S, both hormones are mentioned together in the following text. Biosynthesis DHEA is the steroid hormone belonging to the weak androgens. DHEA and DHEA-S are the major C19 steroids produced from cholesterol by the zona reticularis of the adrenal cortex (Fig.2). DHEA is also produced in small quantities in the gonads (testis and ovary3,8,14), in adipose tissue and in the brain. From this point of view DHEA belongs to the neurosteroids22.
  • Steroids and Other Appearance and Performance Enhancing Drugs (Apeds) Research Report

    Steroids and Other Appearance and Performance Enhancing Drugs (Apeds) Research Report

    Research Report Revised Febrero 2018 Steroids and Other Appearance and Performance Enhancing Drugs (APEDs) Research Report Table of Contents Steroids and Other Appearance and Performance Enhancing Drugs (APEDs) Research Report Introduction What are the different types of APEDs? What is the history of anabolic steroid use? Who uses anabolic steroids? Why are anabolic steroids misused? How are anabolic steroids used? What are the side effects of anabolic steroid misuse? How does anabolic steroid misuse affect behavior? What are the risks of anabolic steroid use in teens? How do anabolic steroids work in the brain? Are anabolic steroids addictive? How are anabolic steroids tested in athletes? What can be done to prevent steroid misuse? What treatments are effective for anabolic steroid misuse? Where can I get further information about steroids? References Page 1 Steroids and Other Appearance and Performance Enhancing Drugs (APEDs) Research Report Esta publicación está disponible para su uso y puede ser reproducida, en su totalidad, sin pedir autorización al NIDA. Se agradece la citación de la fuente, de la siguiente manera: Fuente: Instituto Nacional sobre el Abuso de Drogas; Institutos Nacionales de la Salud; Departamento de Salud y Servicios Humanos de los Estados Unidos. Introduction Appearance and performance enhancing drugs (APEDs) are most often used by males to improve appearance by building muscle mass or to enhance athletic performance. Although they may directly and indirectly have effects on a user’s mood, they do not produce a euphoric high, which makes APEDs distinct from other drugs such as cocaine, heroin, and marijuana. However, users may develop a substance use disorder, defined as continued use despite adverse consequences.